Nicotinamide riboside
Accessible · Evidence and recent research
Notify me when meaningful evidence changes.
Where things stand
Nicotinamide riboside is another way researchers try to raise NAD levels. A small randomized trial in middle-aged and older adults showed that it raises blood NAD, with exploratory findings that motivated further cardiovascular research. Successfully changing a molecule is an early research step; the clinical benefits and implications for lifespan require separate demonstration. Source ↗ Recently: The latest trial-registry update in our collection is dated Oct 27, 2026: “FEAST and HOPE: Redox PSC Pilot Study in PSC”. Its implications have not yet been summarized in a source-checked review. Read update ↗
AI-written overview · not expert-reviewed · Background sources checked Sep 23, 2026 · Recent updates cover the last 30 days of this collection. A new report does not automatically change the evidence assessment.
Background and coverage
- Regulatory status
- Supplement
- Availability
- Widely available
- Category
- Accessible
- Human results verified here
- 0
Evidence collection is needs review. 0 approved assessments; 16 assessments awaiting review; 1 published studies with verified results. Safety: not assessed.
Recorded evidence activity (experimental)
A numeric breakdown will be available after baseline review. Safety is not yet assessed.
What changed
Evidence events affecting this intervention
FEAST and HOPE: Redox PSC Pilot Study in PSC
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
The Effect of Exercise and Nicotinamide Riboside on Muscle Health and Insulin Resistance in Adult Survivors of Childhood Cancer With Prediabetes: A Pilot Feasibility Study
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
The Benefits of Nicotinamide Riboside Upon Cognition and Sleep in Older Veterans
Trial registry update: RECRUITING. No results reported in the supplied registry record.
A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study. Extension Protocol
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation &Amp;Amp;Amp;Amp; Metabolic Rate
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Efficacy of a Single Dose of Nicotinamide Riboside (NR) on Sleep: A Randomized Controlled Study
Trial registry update: COMPLETED. No results reported in the supplied registry record.
Nicotinamide Riboside and Milk Production in the NICU
Trial registry update: RECRUITING. No results reported in the supplied registry record.
The Efficacy and Safety of a Mental Intervention Program vs. Usual Care and Nicotinamide Riboside (NR) vs. Placebo for Improving Health-related Quality of Life in Long Covid: A 2 x 2 Factorial Randomized Controlled Trial
Trial registry update: COMPLETED. No results reported in the supplied registry record.
Nicotinamide Riboside to Improve Functioning in PAD
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
Metformin has extensive preclinical evidence but limited clinical proof of geroprotective effects in systematic review.
This systematic review examined pharmacological interventions targeting aging pathways, including metformin, from literature published January 2010–May 2026. Metformin and rapamycin had among the most extensive preclinical and translational evidence, but the review found that clinical evidence for broadly applicable geroprotection remains limited. The authors emphasize a substantial gap between mechanistic plausibility and clinically validated geroprotection in humans.
Assessment history
The 25 most recent recorded changes, including corrections and backfill
Human studies with verified results
No published human results verified in this collection yet
Animal and mechanistic evidence
No preclinical studies tracked yet